INT2681

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.32
First Reported 1979
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 11
Total Number 12
Disease Relevance 5.98
Pain Relevance 1.27

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Thra) mitochondrion (Thra) nucleus (Thra)
DNA binding (Thra) nucleic acid binding transcription factor activity (Thra) transcription factor binding (Thra)
Anatomy Link Frequency
lower body 1
brain 1
body 1
Thra (Mus musculus)
Pain Link Frequency Relevance Heat
fibrosis 50 99.84 Very High Very High Very High
Clonidine 7 99.22 Very High Very High Very High
abdominal pain 10 90.60 High High
headache 10 88.24 High High
Angina 10 86.64 High High
withdrawal 10 85.08 High High
Central nervous system 1 75.56 Quite High
anesthesia 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hepatitis C Virus Infection 520 99.92 Very High Very High Very High
Fibrosis 40 99.84 Very High Very High Very High
Body Weight 50 99.18 Very High Very High Very High
Hepatitis 20 96.56 Very High Very High Very High
Hypertension 1 96.32 Very High Very High Very High
Suicidal Behaviour 10 92.72 High High
Aggression 10 92.36 High High
Chronic Hepatitis 30 91.20 High High
Abdominal Pain 10 90.60 High High
Vomiting 10 89.84 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Long-term clonidine therapy resulted in decreased MAP and RVR associated with the suppression of supine but not upright PRA.
RVR Binding (associated) of associated with clonidine
1) Confidence 0.32 Published 1979 Journal Clin. Pharmacol. Ther. Section Abstract Doc Link 498699 Disease Relevance 0.10 Pain Relevance 0.61
BMI was not associated with RVR (Table 3).
RVR Binding (associated) of
2) Confidence 0.32 Published 2010 Journal Journal of Viral Hepatitis Section Body Doc Link PMC2810441 Disease Relevance 0.13 Pain Relevance 0
The results of the multiple logistic regression analyses demonstrated that baseline factors independently associated with a RVR included serum HCV RNA ?
RVR Binding (associated) of associated with hepatitis c virus infection
3) Confidence 0.24 Published 2010 Journal Journal of Viral Hepatitis Section Body Doc Link PMC2810441 Disease Relevance 1.20 Pain Relevance 0.31
2 (P = 0.0001) were associated with RVR.
RVR Binding (associated) of
4) Confidence 0.24 Published 2010 Journal Journal of Viral Hepatitis Section Body Doc Link PMC2810441 Disease Relevance 0.96 Pain Relevance 0.14
Limited data have been published regarding the factors associated with RVR and cEVR.
RVR Binding (associated) of
5) Confidence 0.24 Published 2010 Journal Journal of Viral Hepatitis Section Body Doc Link PMC2810441 Disease Relevance 0.45 Pain Relevance 0.04
We retrospectively examined baseline and on-treatment factors associated with RVR (HCV RNA undetectable at week 4) and cEVR (HCV RNA undetectable at week 12, regardless of week 4 response).
RVR Spec (examined) Binding (associated) of associated with hepatitis c virus infection
6) Confidence 0.24 Published 2010 Journal Journal of Viral Hepatitis Section Abstract Doc Link PMC2810441 Disease Relevance 0.75 Pain Relevance 0
In conclusion, several baseline and on-treatment factors were associated with RVR and cEVR to peginterferon alfa-2a plus ribavirin in difficult-to-treat HCV genotype-1 patients, providing important prognostic information on the antiviral response in a patient cohort that is reflective of the general chronic hepatitis C population.



RVR Binding (associated) of associated with chronic hepatitis and hepatitis c virus infection
7) Confidence 0.24 Published 2010 Journal Journal of Viral Hepatitis Section Abstract Doc Link PMC2810441 Disease Relevance 0.73 Pain Relevance 0
In the univariate analysis, body weight and on-treatment drug exposure were both associated with RVR and cEVR.
RVR Binding (associated) of in body associated with body weight
8) Confidence 0.24 Published 2010 Journal Journal of Viral Hepatitis Section Body Doc Link PMC2810441 Disease Relevance 0.19 Pain Relevance 0
Identifying the baseline and on-treatment factors, both virus and patient related, that are associated with RVR and cEVR to therapy with peginterferon alfa-2a plus ribavirin may help predict a patient’s response to treatment, as well as provide important information that can be used to improve viral outcomes [15–17].
RVR Binding (associated) of
9) Confidence 0.24 Published 2010 Journal Journal of Viral Hepatitis Section Body Doc Link PMC2810441 Disease Relevance 0.14 Pain Relevance 0
Lower baseline viral load (<400 000 IU/mL) was also the only significant factor associated with a RVR (OR: 3.052; 95% CI 1.706–5.458) in 200 previously untreated Taiwanese patients infected with HCV genotype 1 who were randomized to treatment with peginterferon alfa-2a plus ribavirin for either 24 or 48 weeks [21].
RVR Binding (associated) of associated with hepatitis c virus infection
10) Confidence 0.21 Published 2010 Journal Journal of Viral Hepatitis Section Body Doc Link PMC2810441 Disease Relevance 0.79 Pain Relevance 0.12
A few studies have shown that in patients receiving peginterferon alfa plus ribavirin, lower viral load, younger age, lower body weight and absence of advanced fibrosis may be associated with a RVR [8,19–21].
RVR Binding (associated) of in lower body associated with fibrosis and body weight
11) Confidence 0.21 Published 2010 Journal Journal of Viral Hepatitis Section Body Doc Link PMC2810441 Disease Relevance 0.55 Pain Relevance 0.05
Selected peptide GYR and control peptide RVR are both positively charged (Table I), yet GYR shows a significantly higher binding to the brain than RVR.
RVR Binding (binding) of in brain
12) Confidence 0.16 Published 2010 Journal Pharm Res Section Body Doc Link PMC2837178 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox